The CJC-1295 and ipamorelin stack builds muscle the way training and sleep do, slowly and modestly, by raising your own IGF-1. No published trial has ever measured muscle gain from this specific pair, and it is not a steroid. The honest version is smaller than the marketing.
The CJC-1295 and ipamorelin stack builds muscle the way training and sleep build muscle: slowly and modestly, by raising the body's own growth hormone and IGF-1. IGF-1 is the signal that tells muscle tissue to grow [7], and this pair raises it through two pathways at once. What it does not do is act like a steroid, and no published trial has ever measured muscle gain from this specific combination. The honest version is smaller than the marketing and worth understanding before you pay for it.
- The stack raises GH through two receptors: CJC-1295 on the GHRH receptor, ipamorelin on the ghrelin receptor [2][3]
- Higher IGF-1 drives skeletal muscle protein synthesis, the real mechanism behind any lean-mass effect [7]
- A GHRH analog plus a secretagogue produced GH well above the sum of each alone in humans, though the study used GHRP-6, not ipamorelin [4]
- Controlled GH data shows lean body mass rises while measured strength and exercise capacity do not [5]
- No published human trial has measured muscle growth from CJC-1295 with ipamorelin specifically
- It is not a steroid; it works upstream through the pituitary and carries no androgenic action
- Both peptides are compounded, not FDA-approved, and banned in tested sport [9][10]
How the Stack Is Supposed to Build Muscle
The muscle claim runs through IGF-1, not through the peptides directly. Growth hormone released by the pituitary travels to the liver, which produces IGF-1, and IGF-1 regulates skeletal muscle hypertrophy by activating satellite cells and the protein-synthesis pathways downstream [7]. Raise IGF-1 and you raise the input to muscle growth. That is the entire mechanistic basis for the stack.
The stack raises it from two directions. CJC-1295 is a long-acting GHRH analog that binds the GHRH receptor and, because it bioconjugates to albumin, keeps GH and IGF-1 elevated for days; a single dose raised IGF-1 1.5 to 3-fold for 9 to 11 days [1][2]. Ipamorelin adds a second, sharper pulse through the ghrelin receptor without raising cortisol or prolactin [3]. Two doors into the same pituitary.
What the Combination Evidence Actually Shows
The strongest point in the stack's favor is that two pathways beat one. When healthy people received a GHRH analog and a secretagogue separately and together, the combination produced GH area under the curve well above the arithmetic sum of each alone [4]. That supra-additive result is real, and it is measured in humans.
That combination study used GHRP-6, an older secretagogue, not ipamorelin, and it measured GH over hours, not muscle over months [4]. The two-pathway principle holds. The specific effect of CJC-1295 with ipamorelin on muscle has never been measured in a published trial.
When you look at what elevated GH actually does to the body in controlled data, the muscle story gets narrower. A systematic review of growth hormone in athletes found lean body mass increased, but part of that gain was fluid retention, and neither strength nor exercise capacity improved measurably [5]. Bigger on a scale is not stronger in the gym.
How Much, and How Fast
Modest, and over months. The closest long-term GHRH-analog data comes from nightly dosing in older adults: over 16 weeks, lean body mass rose in men with no significant change in fat mass [6]. That is a real change, small in size and measured across a season, not a transformation in a few weeks.
Two people on the same protocol will not get the same result. Baseline IGF-1, training load, protein intake, and sleep move the outcome more than dose tweaks do. The stack raises the ceiling on lean-mass signaling. Whether you reach it depends on the work, and sleep is part of that work, since the largest natural GH pulse still comes during slow-wave sleep [8].
Why It Is Not a Steroid
This is the most common misunderstanding, and the mechanism settles it. Anabolic steroids are androgen-receptor agonists that drive protein synthesis in muscle directly, regardless of feedback. CJC-1295 and ipamorelin do none of that. They prompt the pituitary to release its own GH, which the liver converts to IGF-1 [1][3]. Somatostatin feedback still limits how far the axis can be pushed, the pituitary is not suppressed, and there is no androgenic load on the prostate, hair, or lipids.
| Property | CJC-1295 + ipamorelin | Anabolic steroid |
|---|---|---|
| Primary target | Pituitary GHRH and ghrelin receptors [2][3] | Androgen receptor |
| Active molecule | Your own GH, then IGF-1 [1] | Synthetic androgen |
| Feedback control | Limited by somatostatin | None |
| Lean-mass effect | Modest, IGF-1 mediated [6][7] | Large, direct |
| Anti-doping status | Prohibited, GH releasing factors [10] | Prohibited |
Who the Stack Actually Fits
A narrow group, honestly. An adult with a documented low or low-normal IGF-1 for their age, training seriously and eating enough protein, under a prescriber who tests before prescribing, has the most to gain because there is real headroom to restore. Someone with a mid-normal IGF-1, good sleep, and a physique goal is more likely to feel the cost than the effect.
- Adults with a documented low or low-normal baseline IGF-1, under monitoring
- People training consistently, since the peptides raise the ceiling but not the effort [5]
- Not for anyone with active malignancy, since IGF-1 promotes cell growth
- Not for anyone subject to anti-doping testing; both peptides are banned at all times [10]
- Not for anyone expecting steroid-like size or rapid results
The trade-off is straightforward. The two-pathway GH rise is genuine and the individual peptides are studied, but the specific stack's muscle effect rests on mechanism and user reports, not a randomized endpoint. FDA has flagged these peptides among bulk substances that may present compounding safety risks, and neither is FDA-approved [9]. Treat confident before-and-after promises with the skepticism the evidence warrants.
CJC-1295 with ipamorelin is two active peptides on different clocks, and the lean-mass case only holds if the IGF-1 actually moves. SystemLabs tests IGF-1 before prescribing, formulates the stack from licensed U.S. pharmacies on clinical indication, and retests at 90 days, so you are measuring the response instead of trusting a product page.
Frequently Asked Questions
Does CJC-1295 and ipamorelin build muscle?
There is no published human trial of this combination showing muscle growth. It raises IGF-1, the signal that drives skeletal muscle protein synthesis [7], so it supports lean-mass gain rather than causing it outright. Controlled GH data shows lean body mass rises while strength does not [5], and the effect depends on training and protein as much as on the peptides.
Is CJC-1295 and ipamorelin a steroid?
No. Steroids act directly on androgen receptors in muscle. This stack prompts the pituitary to release its own growth hormone, which the liver converts to IGF-1 [1][3]. It carries no androgenic load, and somatostatin feedback keeps the axis in check, which is why the muscle effect is smaller and the risk profile is different.
How much muscle can you gain on CJC-1295 and ipamorelin?
Modest, and over months. The nearest long-term GHRH-analog data measured lean-mass gain in men over 16 weeks, with no big change in fat mass [6]. Expect a small, slow lean-mass shift alongside training, not the rapid size steroids produce. Individual results vary with baseline IGF-1, diet, and sleep.
How long until CJC-1295 and ipamorelin affect body composition?
IGF-1 rises within days of dosing CJC-1295 [1], but visible body-composition change runs slower. Judge it at 3 to 6 months with an IGF-1 retest, not in the first few weeks. Sleep improvement is usually the first thing people notice [8].
Is CJC-1295 and ipamorelin better than steroids for muscle?
They are not comparable tools. Steroids produce larger, faster muscle gain by acting directly on muscle, with the associated risks. This stack works upstream through the pituitary, so the effect is smaller and slower but without androgenic load [1][3]. Neither is a shortcut, and both are banned in tested sport [10].
Is CJC-1295 and ipamorelin legal and approved for muscle growth?
Neither peptide is FDA-approved, and the FDA has flagged both among bulk substances that may present compounding safety risks [9]. There is no approved indication for muscle growth. Both are also on the WADA prohibited list at all times, so tested athletes cannot use them [10].
References
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Journal of Clinical Endocrinology & Metabolism, 2006. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
- Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Endocrinology, 2005. PMID: 15817669. https://pubmed.ncbi.nlm.nih.gov/15817669/
- Ipamorelin, the first selective growth hormone secretagogue European Journal of Endocrinology, 1998. PMID: 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
- Growth hormone (GH) secretion in active acromegaly after the combined administration of GH-releasing hormone and GH-releasing peptide-6 Journal of Clinical Endocrinology & Metabolism, 1994. PMID: 8045963. https://pubmed.ncbi.nlm.nih.gov/8045963/
- Systematic review: the effects of growth hormone on athletic performance Annals of Internal Medicine, 2008. PMID: 18347346. https://pubmed.ncbi.nlm.nih.gov/18347346/
- Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women Journal of Clinical Endocrinology & Metabolism, 1997. PMID: 9141536. https://pubmed.ncbi.nlm.nih.gov/9141536/
- Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy Cells, 2020. PMID: 32858949. https://pubmed.ncbi.nlm.nih.gov/32858949/
- Growth hormone secretion during sleep Journal of Clinical Investigation, 1968. PMID: 5675428. https://pubmed.ncbi.nlm.nih.gov/5675428/
- Certain bulk drug substances for use in compounding that may present significant safety risks FDA.gov, Human Drug Compounding, 2026. Content current as of 04/22/2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- The 2026 Prohibited List: International Standard, section S2.2.4 growth hormone releasing factors World Anti-Doping Agency, 2026. WADA 2026 Prohibited List. https://www.wada-ama.org/en/resources/2026-prohibited-list
